Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (“Fulc
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
12:11pm, Friday, 13'th Sep 2024
The phase III REACH study evaluating Fulcrum's losmapimod for treating facioscapulohumeral muscular dystrophy fails to meet the primary endpoint.
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")
Fulcrum Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - FULC
05:00pm, Thursday, 12'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
Fulcrum Therapeutics Inc May Have Violated Securities Laws And Stockholders Are Invited By The Schall Law Firm To Help With An Inquiry
04:45pm, Thursday, 12'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther
Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - FULC
04:00pm, Thursday, 12'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
12:24pm, Thursday, 12'th Sep 2024
LOS ANGELES--(BUSINESS WIRE)--FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")
― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ―
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
02:28pm, Monday, 09'th Sep 2024
BofA Securities has upgraded Fulcrum Therapeutics FULC ahead of the company's phase 3 losmapimod readout, expected by the end of October for Facioscapulohumeral muscular dystrophy (FSHD).
Fulcrum Therapeutics to Participate in Upcoming September Conferences
04:05pm, Tuesday, 27'th Aug 2024
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay
09:13am, Tuesday, 27'th Aug 2024
Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay are included in this Analyst Blog.
5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts
03:45pm, Monday, 26'th Aug 2024
We have narrowed our search to five small-cap stocks that have strong momentum. These are FULC, HRTG, SWIM, SHIP and BWAY.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 23'rd Aug 2024
CAMBRIDGE, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
